Ginsberg, Henry N.

Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome

Stroes, E. S. G., Alexander, V. J., Karwatowska-Prokopczuk, E., Hegele, R. A., Arca, M., Ballantyne, C. M., Soran, H., Prohaska, T. A., Xia, S., Ginsberg, H. N., et al. (2024) · New England Journal of Medicine

Lipid metabolism and disordersPancreatitis Pathology and Treatment

Cited by 271

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients

Fruchart, J.-C., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · Diabetes and Vascular Disease Research

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 260

New Perspectives on Atherogenesis: Role of Abnormal Triglyceride-Rich Lipoprotein Metabolism

Ginsberg, H. N. (2002) · Circulation

Atherosclerosis and Cardiovascular DiseasesCholesterol and Lipid Metabolism

Cited by 255

Safety and efficacy of Omacor in severe hypertriglyceridemia

Harris, W. S., Ginsberg, H. N., Arunakul, N., Shachter, N. S., Windsor, S. L., Adams, M., Berglund, L., & Osmundsen, K. (1997) · Journal of Cardiovascular Risk

Lipoproteins and Cardiovascular HealthFatty Acid Research and Health

Cited by 252

Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans

Reyes-Soffer, G., Pavlyha, M., Ngai, C., Thomas, T., Holleran, S., Ramakrishnan, R., Karmally, W., Nandakumar, R., Fontanez, N., Obunike, J., et al. (2017) · Circulation

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 240

Diabetic Dyslipidemia

Chahil, T. J., & Ginsberg, H. N. (2006) · Endocrinology and Metabolism Clinics of North America

Diabetes, Cardiovascular Risks, and LipoproteinsLipoproteins and Cardiovascular Health

Cited by 233

Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol

Horowitz, B. S., Goldberg, I. J., Merab, J., Vanni, T. M., Ramakrishnan, R., & Ginsberg, H. N. (1993) · Journal of Clinical Investigation

Cholesterol and Lipid MetabolismLipoproteins and Cardiovascular Health

Cited by 231

Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease

Chait, A., Ginsberg, H. N., Vaisar, T., Heinecke, J. W., Goldberg, I. J., & Bornfeldt, K. E. (2020) · Diabetes

Diabetes, Cardiovascular Risks, and LipoproteinsLipoproteins and Cardiovascular Health

Cited by 229

Prevention of Cardiovascular Disease in Persons with Type 2 Diabetes Mellitus: Current Knowledge and Rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial

Goff, D. C., Gerstein, H. C., Ginsberg, H. N., Cushman, W. C., Margolis, K. L., Byington, R. P., Buse, J. B., Genuth, S., Probstfield, J. L., & Simons-Morton, D. G. (2007) · The American Journal of Cardiology

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 229

Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia.

Ginsberg, H., Kimmerling, G., Olefsky, J. M., & Reaven, G. M. (1975) · Journal of Clinical Investigation

Diabetes, Cardiovascular Risks, and LipoproteinsPancreatic function and diabetes

Cited by 225

Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne.

Bershad, S., Rubinstein, A., Paterniti, J. R., Le, N.-A., Poliak, S. C., Heller, B., Ginsberg, H. N., Fleischmajer, R., & Brown, W. V. (1985) · New England Journal of Medicine

Acne and Rosacea Treatments and EffectsLipoproteins and Cardiovascular Health

Cited by 217

Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement

Hegele, R. A., Borén, J., Ginsberg, H. N., Arca, M., Averna, M., Binder, C. J., Calabresi, L., Chapman, M. J., Cuchel, M., von Eckardstein, A., et al. (2020) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 204

Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus

Nagashima, K., Lopez, C., Donovan, D., Ngai, C., Fontanez, N., Bensadoun, A., Fruchart-Najib, J., Holleran, S., Cohn, J. S., Ramakrishnan, R., et al. (2005) · Journal of Clinical Investigation

Lipid metabolism and disordersPeroxisome Proliferator-Activated Receptors

Cited by 201

Cognitive Function and Brain Structure in Persons With Type 2 Diabetes Mellitus After Intensive Lowering of Blood Pressure and Lipid Levels: A Randomized Clinical Trial

Williamson, J. D., Launer, L. J., Bryan, R. N., Coker, L. H., Lazar, R. M., Gerstein, H. C., Murray, A. M., Sullivan, M. D., Horowitz, K. R., Ding, J., et al. (2014) · JAMA Internal Medicine

Dementia and Cognitive Impairment ResearchDiabetes Treatment and Management

Cited by 187

Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes

Elam, M. B., Ginsberg, H. N., Lovato, L. C., Corson, M., Largay, J., Leiter, L. A., Lopez, C., O’Connor, P. J., Sweeney, M. E., Weiss, D., et al. (2017) · JAMA Cardiology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 185

Comparison of monounsaturated fat with carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: studies in the fasting and postprandial states

Berglund, L., Lefevre, M., Ginsberg, H. N., Kris-Etherton, P. M., Elmer, P. J., Stewart, P. W., Ershow, A., Pearson, T. A., Dennis, B. H., Roheim, P. S., et al. (2007) · The American Journal of Clinical Nutrition

Fatty Acid Research and HealthDiet, Metabolism, and Disease

Cited by 172

No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY phase 3 studies

Colhoun, H. M., Ginsberg, H. N., Robinson, J. G., Leiter, L. A., Müller-Wieland, D., Henry, R. R., Cariou, B., Baccara-Dinet, M. T., Pordy, R., Merlet, L., et al. (2016) · European Heart Journal

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 172

Long term cholesterol-lowering effects of psyllium as an adjunct to diet therapy in the treatment of hypercholesterolemia

Anderson, J. W., Davidson, M. H., Blonde, L., Brown, W. V., Howard, W. J., Ginsberg, H., Allgood, L. D., & Weingand, K. W. (2000) · The American Journal of Clinical Nutrition

Lipoproteins and Cardiovascular HealthFood composition and properties

Cited by 172

Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants

Mychaleckyj, J. C., Craven, T., Nayak, U., Buse, J., Crouse, J. R., Elam, M., Kirchner, K., Lorber, D., Marcovina, S., Sivitz, W., et al. (2012) · Diabetes Care

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 149

Moderate Ethanol Ingestion and Plasma Triglyceride Levels: A Study in Normal and Hypertriglyceridemic Persons

GINSBERG, H., OLEFSKY, J., FARQUHAR, J. W., & REAVEN, G. M. (1974) · Annals of Internal Medicine

Alcohol Consumption and Health EffectsLipid metabolism and disorders

Cited by 144

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology

Peroxisome Proliferator-Activated ReceptorsLipoproteins and Cardiovascular Health

Cited by 140

Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes

Koska, J., Saremi, A., Howell, S., Bahn, G., De Courten, B., Ginsberg, H., Beisswenger, P. J., Reaven, P. D., & for the VADT Investigators (2018) · Diabetes Care

Advanced Glycation End Products researchDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 134

Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control

Ray, K. K., Ginsberg, H. N., Davidson, M. H., Pordy, R., Bessac, L., Minini, P., Eckel, R. H., & Cannon, C. P. (2016) · Circulation

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 127

Relative Atherogenicity and Predictive Value of Non–High-Density Lipoprotein Cholesterol for Coronary Heart Disease

Miller, M., Ginsberg, H. N., & Schaefer, E. J. (2008) · The American Journal of Cardiology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 102